Cancer News and Research

Latest Cancer News and Research

GHX OnDemand AP software-as-a-service solution helps hospitals reduce invoicing processing costs

A growing number of healthcare providers are using the OnDemand AP(SM) solution by GHX to automate and streamline their accounts payable processes, reducing invoice processing costs and cycle time, and improving internal controls and cash flow management. With OnDemand AP, hospitals can receive 100 percent of their invoices electronically, even from suppliers who do not currently support electronic invoicing. By eliminating the need for manual data entry and accelerating invoice approval, hospitals can reduce invoicing processing costs by more than 80 percent.

20 Aug 2009

National Science Foundation funds CMU for developing revolutionary computational tools

A multidisciplinary team led by Carnegie Mellon University computer scientist Edmund M. Clarke has received a five-year, $10 million grant from the National Science Foundation's Expeditions in Computing program to create revolutionary computational tools that will advance science on a broad array of fronts, from discovering new cancer treatments to designing safer aircraft.

20 Aug 2009

DNA-encased carbon nanotubes used for treating human prostate cancer tumors in mice

Researchers at Wake Forest University School of Medicine have destroyed prostate cancer tumors in mice by injecting them with specially-coated, miniscule carbon tubes and then superheating the tubes with a brief zap of a laser.

20 Aug 2009

AMDL reports revenues of $3.2 million for second quarter of 2009

AMDL Inc., a US-based pharmaceutical company with major operations in China, today reported unaudited results and the filing of its Form 10-Q with the Securities and Exchange Commission ("SEC") for fiscal second quarter 2009.

19 Aug 2009

Brits risk late cancer diagnosis because of poor symptom awareness

One in seven people cannot name a single symptom of cancer, according to a Cancer Research UK survey published Monday.

19 Aug 2009

Steroid hormones found to affect gene activity

Intermittent signaling by steroid hormones can affect the way genes are expressed in rodents, according to research by scientists at the University of Bristol and the National Cancer Institute (NCI), USA. This work has major implications for understanding how steroids work and opens novel avenues for new therapies.

19 Aug 2009

Nano-bio material kills cancer cells, leaves healthy cells in unharmed

Scientists from the U.S. Department of Energy's (DOE) Argonne National Laboratory and the University of Chicago's Brain Tumor Center have developed a way to target brain cancer cells using inorganic titanium dioxide nanoparticles bonded to soft biological material.

19 Aug 2009

News outlets continue to explain how end-of-life care counseling works

NPR talks with Dr. David Casarett, associate professor of medicine at the University of Pennsylvania who started the palliative care service at the VA hospital in Philadelphia, about "the rhetoric around the end-of-life issues addressed in some of the proposed health care legislation" (Block, 8/18).

19 Aug 2009

New tool for scientists - light used to manipulate cell movement

One of the biggest challenges in scientists' quest to develop new and better treatments for cancer is gaining a better understanding of how and why cancer spreads. Recent breakthroughs have uncovered how different cellular proteins are turned 'on' or 'off' at the molecular level, but much remains to be understood about how protein signaling influences cell behavior.

19 Aug 2009

U.S. FDA approval of miconazole MBT represents a significant milestone for Strativa Pharmaceuticals

Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: PRX), today announced that the U.S. Food and Drug Administration (FDA) has accepted the new drug application (NDA) for miconazole Lauriad((R)) mucoadhesive buccal tablets (MBT) to treat oropharyngeal candidiasis (OPC).

19 Aug 2009

Light Sciences Oncology announces Phase 2 trial of Aptocine in Benign Prostatic Hyperplasia

Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.

19 Aug 2009

Gentium reports results from phase 3 trial of defibrotide for severe veno-occlusive disease

Gentium S.p.A. has announced top-line results from a historically controlled, multicenter, open label, Phase III trial designed to evaluate the safety and efficacy of 25 mg/kg/day of Defibrotide for the treatment of severe veno-occlusive disease (sVOD) in hematopoietic stem cell transplant (SCT) patients.

19 Aug 2009

ImmunoCellular Therapeutics to participate in the Southern California Investor Conference

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that it will participate in the Southern California Investor Conference being held in Newport Beach, CA, on Tuesday August 18, 2009.

19 Aug 2009

CEL-SCI expands work on current H1N1 virus vaccine

CEL-SCI Corporation has announced that it is expanding the scope of its work towards creating a novel treatment and vaccination against the current H1N1 virus, as well as a future mutated form in which the virus has acquired greater morbidity and mortality.

19 Aug 2009

New "micropatterning" method useful in gene expression studies

Like oil and water, two water-based liquids can mingle without mixing in a new University of Michigan technology developed for biological experiments.

19 Aug 2009

Light-activated delivery system enhances anti-tumour drug potency

The effects of tumour-targeting drugs in mice are significantly enhanced by PCI Biotech's light-activated delivery system, a new study shows. Researchers say this dual therapy approach could be employed to increase the effect and lower the side effects of anti-cancer drugs in humans.

19 Aug 2009

BioDelivery Sciences International utilizes ICR's services for shareholder communications program

BioDelivery Sciences International, Inc. (BDSI®) (Nasdaq:BDSI) today announced that it has retained ICR, a leading investor relations and strategic advisory firm, to assist in the Company's shareholder communications program. ICR, founded in 1998 by a group of former institutional capital markets professionals, is headquartered in Westport, Connecticut, with offices in Westport, New York, Los Angeles, Boston, Chicago, Minneapolis, Beijing, and Shanghai.

19 Aug 2009

Forty-six uninsured San Diego County patients to receive free surgeries, procedures

Forty-six uninsured San Diego County patients will receive donated outpatient surgeries and procedures on Saturday, August 22, 2009, through an ongoing partnership between Project Access San Diego (PASD), a program of the San Diego County Medical Society Foundation, Kaiser Permanente and the Alliance Healthcare Foundation. PASD mobilizes medical volunteers to provide free surgeries and procedures to uninsured San Diegans.

19 Aug 2009

Discovery of mechanism that allows hepatitis C virus to remain in the body for decades

A study published in the Proceedings of the National Academy of Sciences (PNAS) shows that the virus blocks the actions of a specific ion channel in the cell membrane that would usually trigger apoptosis - the cell's self-destruct programme - and in doing so, has evolved another way of protecting itself from being eliminated from the body.

19 Aug 2009

Arzoxifene phase 3 study results reported by Lilly

Eli Lilly and Company announced today that initial results from its pivotal, five-year, Phase III GJAD "GENERATIONS" trial for arzoxifene met its primary endpoints of significantly reducing the risk of vertebral fracture and invasive breast cancer in postmenopausal women.

19 Aug 2009

Cancer News and Research

Latest Cancer News and Research

GHX OnDemand AP software-as-a-service solution helps hospitals reduce invoicing processing costs

National Science Foundation funds CMU for developing revolutionary computational tools

DNA-encased carbon nanotubes used for treating human prostate cancer tumors in mice

AMDL reports revenues of $3.2 million for second quarter of 2009

Brits risk late cancer diagnosis because of poor symptom awareness

Steroid hormones found to affect gene activity

Nano-bio material kills cancer cells, leaves healthy cells in unharmed

News outlets continue to explain how end-of-life care counseling works

New tool for scientists - light used to manipulate cell movement

U.S. FDA approval of miconazole MBT represents a significant milestone for Strativa Pharmaceuticals

Light Sciences Oncology announces Phase 2 trial of Aptocine in Benign Prostatic Hyperplasia

Gentium reports results from phase 3 trial of defibrotide for severe veno-occlusive disease

ImmunoCellular Therapeutics to participate in the Southern California Investor Conference

CEL-SCI expands work on current H1N1 virus vaccine

New "micropatterning" method useful in gene expression studies

Light-activated delivery system enhances anti-tumour drug potency

BioDelivery Sciences International utilizes ICR's services for shareholder communications program

Forty-six uninsured San Diego County patients to receive free surgeries, procedures

Discovery of mechanism that allows hepatitis C virus to remain in the body for decades

Arzoxifene phase 3 study results reported by Lilly

Industry Focus eBook - Immunology (3rd edition) eBook

How industrial hygiene flow calibration supports defensible exposure data

How electrical engineering ensures accurate calibration and patient safety

The importance of ketones from a clinical and medical perspective

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Immunology (3rd edition) eBook

How industrial hygiene flow calibration supports defensible exposure data

How electrical engineering ensures accurate calibration and patient safety

The importance of ketones from a clinical and medical perspective

Newsletters you may be interested in